The efficacy and safety of endoscopic ultrasound-guided fine-needle biopsy in gallbladder masses
Ting Tong, Li Tian, Min-Zi Deng, Xue-Jie Chen, Tian Fu, Ke-Jia Ma, Jia-Hao Xu, Xiao-Yan Wang ∗
Endoscopic Center, Department of Gastroenterology, the Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road Yuelu District, Changsha 410013, China
Abstract：Background: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is a widely used modality for acquiring various target samples, but its efficacy in gallbladder masses is unknown. The aim of this ret- rospective study was to evaluate the efficacy and safety of EUS-FNB in patients with gallbladder masses.
Methods: The study samples were composed of patients from March 2015 to July 2019 who needed to identify the nature of gallbladder masses through EUS-FNB. The outcomes of this study were the adequacy of specimens, diagnostic yields, technical feasibility, and adverse events of the EUS-FNB in gallbladder masses.
Results: A total of 27 consecutive patients with a median age of 58 years were included in this study. The 22-gauge FNB needle was feasible in all lesions. The median follow-up period of the patients was 294 days. The specimens sufficient for diagnosis account for 89% (24/27) and 93% (25/27) in cytology and histology, respectively. The overall diagnostic yields for malignancy showed the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 95.45% [95% confidence interval (CI): 75.12%-99.76%], 100% (95% CI: 46.29%-10 0%), 10 0% (95% CI: 80.76%-100%), 83.33% (95% CI: 36.48%- 99.12%), and 96.30% (95% CI: 80.20%-99.99%), respectively. The subgroup analysis revealed that FNB could obtain sufficient specimens and high diagnostic yields in both gallbladder mass < 20.5 mm group and ≥20.5 mm group. One patient experienced mild abdominal pain after the procedure and recovered within one day.
Conclusions: EUS-FNB is a reasonable diagnostic tool for the pretreatment diagnosis of patients with gallbladder masses, especially for patients who may miss the opportunity of surgery and need sufficient specimens to identify the pathological type so as to determine chemotherapy regimens. Further large-scale studies are needed to confirm our conclusion.
2023, Vol. 22 
